104227-87-4|泛昔洛韦|Famciclovir|MFCD00866964-范德生物科技公司

泛昔洛韦

NMR下载 COA and HPLC MSDS下载
names：
Famciclovir
CAS号：
104227-87-4
MDL Number： MFCD00866964
MF(分子式)： C14H19N5O4 MW(分子量)： 321.33
EINECS:630-411-6 Reaxys Number:
Pubchem ID:3324 Brand:BIOFOUNT

泛昔洛韦(104227-87-4,Famciclovir,BRL 42810)是一种鸟嘌呤类似物抗病毒药，用于治疗各种疱疹病毒感染。; IC50值：参见喷昔洛韦;目标：HSV泛昔洛韦是活性抗病毒化合物喷昔洛韦的二乙酰基6-脱氧类似物，可能在治疗中使用由疱疹病毒家族引起的感染。泛昔洛韦，一种合成的无环鸟嘌呤衍生物，是一种前药，口服后可迅速代谢为生物利用度高的抗病毒化合物喷昔洛韦[2]。体外：泛昔洛韦可快速，剂量依赖性地抑制病毒复制并减少丙氨酸。氨基转移酶（ALT），在500 mg tid治疗组中疗效最佳。在整个治疗期间，HBV DNA的降低一直保持。在治疗期间，ALT也稳定下降。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000717-100mg	100mg	99.74%	¥ 1251.00	¥ 1251.00		2-3天	- +	¥ 0.00
YZM000717-50mg	50mg	99.74%	¥ 696.15	¥ 696.15		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	泛昔洛韦(104227-87-4);法昔洛为; 法昔洛韦;1,3-丙二醇，2-（2-（2-氨基-9H-嘌呤-9-基）乙基）-二乙酸酯(酯); 9-（4-乙酰氧基-3-（乙酰氧基甲基）丁-1-基）-2-氨基嘌呤;BRL 42810;BRL-42810;BRL42810;
英文别名	Famciclovir(104227-87-4);BRL-42810；BRL 42810；BRL42810;2-(2-(2-Amino-9H-purin-9-yl)ethyl)propane-1,3-diyl diacetate; 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester; 2-[2-(2-Amino-9H-purin-9-yl)ethyl]-1,3-propanediol Diacetate; Famciclovir; Amciclovir; Famciclover; FaMtrex; FaMciclovir API; Famvir; famcyclovir; FCV; FaMcivir;1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester) ;9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine;famciclovir;Famvir;
CAS号	104227-87-4
SMILES	NC1=NC=C2N=CN(CCC(COC(C)=O)COC(C)=O)C2=N1
Inchi	InChI = 1S / C14H19N5O4 / c1-9（20）22-6-11（7-23-10（2）21）3-4-19-8-17-12-5-16-14（15）18- 13（12）19 / h5,8,11H，3-4,6-7H2,1-2H3，（H2,15,16,18）
InchiKey	GGXKWVWZWMLJEH-UHFFFAOYSA-N
分子式 Formula	C14H19N5O4
分子量 Molecular Weight	321.33
闪点 FP	286.6oC
熔点 Melting point	102-104°C
沸点 Boiling point	550.2oC at 760 mmHg
Polarizability极化度
密度 Density	1.4g/cm3
蒸汽压 Vapor Pressure	3.73E-12mmHg at 25°C
溶解度Solubility	生物体外In Vitro:DMSO溶解度≥ 100 mg/mL(311.21 mM)H2O : 50 mg/mL(155.60 mM;Need ultrasonic)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状	白色晶体灰白色固体粉末,Power
储藏条件 Storage conditions	-20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

泛昔洛韦(104227-87-4,Famciclovir,BRL 42810)毒理性质：

Famciclovir has been associated with a low rate of serum aminotransferase elevations during oral therapy. In pooled analyses of patients on long term suppressive therapy, 3.2% of famciclovir vs 1.5% of placebo recipients had ALT elevations above twice normal. The elevations were transient and asymptomatic and resolved even without dose modification. Since approval, cases of cholestatic jaundice have been reported to the sponsor, but there have been no published cases. Thus, clinically apparent liver disease due to famciclovir must be rare if it occurs at all.

Likelihood score: E (unlikely cause of clinically apparent liver injury).

泛昔洛韦(104227-87-4,Famciclovir,BRL 42810)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags：泛昔洛韦试剂,泛昔洛韦杂质,泛昔洛韦合成,泛昔洛韦中间体,泛昔洛韦密度,泛昔洛韦溶解度,泛昔洛韦旋光度,泛昔洛韦闪点,泛昔洛韦购买,

产品说明	泛昔洛韦(104227-87-4,Famciclovir,BRL 42810)是一种鸟嘌呤类似物抗病毒药物,泛昔洛韦用于治疗各种疱疹病毒感染C50值.
Introduction	泛昔洛韦(104227-87-4,Famciclovir,BRL 42810)is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections.IC50 Value: Refer to penciclovir
Application1	Famciclovir（BRL 42810）是鸟嘌呤类似物，具有抗疱疹病毒活性。
Application2	泛昔洛韦（Famvir）是鸟嘌呤类似物抗病毒药物，用于治疗各种疱疹病毒感染，最常见的是带状疱疹（带状疱疹）。它是喷昔洛韦的前药形式，具有改善的口服生物利用度。
Application3

泛昔洛韦(104227-87-4,Famciclovir,BRL 42810)药理学：

1、泛昔洛韦是一种前药，它经历了快速生物转化为活性抗病毒药喷昔洛韦。Penciclovir是一种抗病毒药物，对1型单纯疱疹病毒（HSV-1）和2型单纯疱疹病毒（HSV-2）和水痘带状疱疹病毒（VZV）具有抑制活性。因此，疱疹病毒DNA的合成和复制被选择性抑制。

2、泛昔洛韦是抗病毒药物喷昔洛韦的二乙酰基6-脱氧前药类似物。口服泛昔洛韦可在体内转化为喷昔洛韦三磷酸，后者对疱疹病毒具有活性，包括单纯疱疹1和2和水痘带状疱疹。该试剂通过竞争性干扰DNA聚合酶来抑制病毒DNA的复制。

3、泛昔洛韦是核酸合成抑制剂可以抑制细胞产生DNA或RNA的化合物。

4、泛昔洛韦是抗病毒剂，可以用于预防或治疗病毒性疾病的药物。它们可能发挥作用的方式包括通过抑制病毒DNA聚合酶来防止病毒复制。与特定的细胞表面受体结合并抑制病毒渗透或脱壳；抑制病毒蛋白质合成；或阻止病毒组装的后期。泛昔洛韦是一种核苷类似物和抗病毒剂，用于治疗带状疱疹和单纯疱疹病毒感染。泛昔洛韦与治疗期间血清中度至中度血清ALT升高率低相关，但与临床上明显的肝损伤无关。

5、泛昔洛韦，也称为泛昔洛韦或BRL-42810，属于称为嘌呤和嘌呤衍生物的有机化合物。这些是含有芳香杂环化合物的嘌呤部分，其上形成有嘧啶稠合到环型圈咪唑环。

6、泛昔洛韦是一种用于治疗急性带状疱疹（带状疱疹）的药物。还用于治疗或抑制免疫活性患者的生殖器疱疹复发和HIV感染患者的复发性皮肤粘膜单纯疱疹感染。泛昔洛韦以固体存在，微溶（在水中）和极弱的酸性（基本上是中性）化合物（基于其pKa）。在多种生物流体（如尿液和血液）中检测到泛昔洛韦。在细胞内，泛昔洛韦主要位于细胞质中。

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

泛昔洛韦(104227-87-4,Famciclovir,BRL 42810)危害标识：

象形图
象形图
信号	Danger
GHS危险说明	Aggregated GHS information provided by 4 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
	H319 (50%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
	H341 (25%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]
	H351 (25%): Suspected of causing cancer [Warning Carcinogenicity]
	H360 (50%): May damage fertility or the unborn child [Danger Reproductive toxicity]
	Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
防范说明代码	P201, P202, P264, P280, P281, P305+P351+P338, P308+P313, P337+P313, P405, and P501
防范说明代码	(The corresponding statement to each P-code can be found at the GHS Classification page.)

Harrell AW, Wheeler SM, Pennick M, Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab Di

Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs. 1995 Aug;50(2):396-415.

Trépo C, Jezek P, Atkinson G, Famciclovir in chronic hepatitis B: results of a dose-finding study. J Hepatol. 2000 Jun;32(6):1011-8.

Filer CW, Ramji JV, Allen GD, Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. Xenobiotica. 1995 May;25(5):477-90.

Wutzler P, Ulbricht A, F?rber I. Antiviral efficacies of famciclovir, valaciclovir, and brivudin in disseminated herpes simplex virus type 1 infection in mice. Intervirology. 1997;40(1):15-21.

泛昔洛韦(104227-87-4,Famciclovir,BRL 42810)参考文献：

1.Interventions for prevention of herpes simplex labialis (cold sores on the lips).
Chi CC1, Wang SH, Delamere FM, Wojnarowska F, Peters MC, Kanjirath PP. Cochrane Database Syst Rev. 2015 Aug 7;8:CD010095. doi: 10.1002/14651858.CD010095.pub2.

BACKGROUND: Herpes simplex labialis (HSL), also known as cold sores, is a common disease of the lips caused by the herpes simplex virus, which is found throughout the world. It presents as a painful vesicular eruption, forming unsightly crusts, which cause cosmetic disfigurement and psychosocial distress. There is no cure available, and it recurs periodically.

2.Treatment of Abdominal Segmental Hernia, Constipation, and Pain Following Herpes Zoster with Paravertebral Block.
Kim S1, Jeon Y. Pain Physician. 2015 Sep-Oct;18(5):E927-9.

Herpes zoster (HZ) most commonly occurs in elderly patients and involves sensory neurons resulting in pain and sensory changes. Clinically significant motor deficits and visceral neuropathies are thought to be relatively rare. A 72-year-old man presented with abdominal segmental hernia, constipation, and pain following HZ in the left T9-10 dermatome. Sixteen days before presentation, he had developed a painful herpetic rash in the left upper abdominal quadrant. Approximately 10 days after the onset of the rash, constipation occurred and was managed with daily oral medication with bisacodyl 5 mg. In addition, 14 days after the onset of HZ, the patient noticed a protrusion of the left upper abdominal wall. Abdominal x-ray, ultrasound of the abdomen, and electrolyte analysis showed no abnormalities. General physical examination revealed a reducible bulge in his left upper quadrant and superficial abdominal reflexes were diminished in the affected region.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开